855291-54-2
855291-54-2
Chemical Structure
ABT-107
- CAS No.: 855291-54-2
- Formula:C19H20N4O
- Molecular Weight:320.39
IUPAC Name: (R)-3-((6-(1H-indol-5-yl)pyridazin-3-yl)oxy)quinuclidine
InChIKey: LUKNJAQKVPBDSC-SFHVURJKSA-N
SMILES: [C@H]1(C2CCN(CC2)C1)OC3=CC=C(C4=CC=C(NC=C5)C5=C4)N=N3
Biological Activity: ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ABT-107 | 99.73% | ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RPR107393 free base | RPR107393 free base is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 free base inhibits rat liver microsomal squalene synthase with an IC50 value of 0.8 nM. RPR107393 free base reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 free base reduces plasma cholesterol in rats and marmosets. RPR107393 free base can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RPR107393 | RPR107393 is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 inhibits rat liver microsomal squalene synthase with an IC50 value of 0.8 nM. RPR107393 reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 reduces plasma cholesterol in rats and marmosets. RPR107393 can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WAY-262611 | 99.96% | WAY-262611 is a Wnt/β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
rel-VU6021625 | 99.67% | rel-VU6021625 is the relative configuration of VU6021625 (HY-160440A). VU6021625 is a potent and selective mAChR M4 antagonist with IC50 values of 0.44 nM and 57 nM for human M4, rat M4, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VU6021625 | VU6021625 is a selective antagonist muscarinic acetylcholine receptors (mAChRs), with the IC50 value of 0.44 nM, 57 nM for human M4 and rat M4, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VQW-765 | 99.58% | VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Branaplam | 98.44% | Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Branaplam hydrochloride | 99.43% | Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MG-V-53 | MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC50 value of 121 nM. MG-V-53 has antitumor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SDH-IN-43 | SDH-IN-43 (Compound i-19) is a succinate dehydrogenase (SDH) inhibitor. SDH-IN-43 shows potent inhibitory activity against caenorhabditis elegans wirh an IC50 of 6.67 μM. SDH-IN-43 can significantly reduce caenorhabditis elegans reproductive ability and movement ability, and is also effective against drug-resistant strains of Levamisole (HY-A0106), Benzimidazole (HY-Y1825), and Ivermectin (HY-15310). SDH-IN-43 can be used for the research of parasite infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. R Scott Bitner, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. [Content Brief]
- [2]. Tanuja Bordia, et al. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277-84. [Content Brief]
